330 related articles for article (PubMed ID: 14583762)
1. Second primary malignancies in thyroid cancer patients.
Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M
Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762
[TBL] [Abstract][Full Text] [Related]
2. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
3. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
5. Leukaemias and cancers following iodine-131 administration for thyroid cancer.
de Vathaire F; Schlumberger M; Delisle MJ; Francese C; Challeton C; de la Genardiére E; Meunier F; Parmentier C; Hill C; Sancho-Garnier H
Br J Cancer; 1997; 75(5):734-9. PubMed ID: 9043033
[TBL] [Abstract][Full Text] [Related]
6. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
7. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
9. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
[TBL] [Abstract][Full Text] [Related]
10. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
11. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
14. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
[TBL] [Abstract][Full Text] [Related]
15. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
16. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.
Chuang SC; Hashibe M; Yu GP; Le AD; Cao W; Hurwitz EL; Rao JY; Neugut AI; Zhang ZF
Cancer Lett; 2006 Jul; 238(1):42-52. PubMed ID: 16039041
[TBL] [Abstract][Full Text] [Related]
18. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
19. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
[TBL] [Abstract][Full Text] [Related]
20. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
